K Hemminki1, X Li. 1. Department of Biosciences at Novum, Karolinska Institute, 141 57 Huddinge, Sweden. kari.hemminki@cnt.ki.se
Abstract
BACKGROUND AND AIMS: Familial risks in liver and biliary cancers have been assessed in small case control studies, usually based on reported, but not medically verified, cancers in family members. Thus the degree of familial clustering for these cancers remains to be established. METHODS: The nationwide Swedish Family-Cancer Database was used, covering 10.2 million individuals for the years 1961-1998 from the Swedish Cancer Registry. Liver and biliary tract cancers were identified from 1121 offspring between the ages of 0 and 66 years and 17 131 parents. Standardised incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated for cancers in family members. RESULTS: All cancers in the liver and biliary system showed a familial SIR of 1.65 (95% CI 1.05-2.46). This was mainly explained by a high risk for familial gall bladder cancer (SIR 5.21 (95% CI 2.07-10.80)) and for familial primary liver cancer with hepatocellular carcinoma histology (SIR 4.69 (95% CI 1.48-11.04)). For gall bladder and hepatocellular cancer, maternal transmission appeared to be favoured. Gall bladder cancer was associated with pancreatic cancer (SIR 2.39 (95% CI 1.23-4.18)). Primary liver cancer was associated with cervical, urinary bladder, and endocrine gland tumours. Cancer in extrahepatic bile ducts was associated with ovarian cancer and that in ampulla of Vater with thyroid cancer; however, these associations may have been fortuitous. CONCLUSIONS: This study has provided the first data on familial clustering of liver and gall bladder cancers, based on medically confirmed records. The risks were so high that heritable factors were likely to contribute, possibly modified by environmental factors. The demonstration of candidate genes would help to further characterise the familial risks.
BACKGROUND AND AIMS: Familial risks in liver and biliary cancers have been assessed in small case control studies, usually based on reported, but not medically verified, cancers in family members. Thus the degree of familial clustering for these cancers remains to be established. METHODS: The nationwide Swedish Family-Cancer Database was used, covering 10.2 million individuals for the years 1961-1998 from the Swedish Cancer Registry. Liver and biliary tract cancers were identified from 1121 offspring between the ages of 0 and 66 years and 17 131 parents. Standardised incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated for cancers in family members. RESULTS: All cancers in the liver and biliary system showed a familial SIR of 1.65 (95% CI 1.05-2.46). This was mainly explained by a high risk for familial gall bladder cancer (SIR 5.21 (95% CI 2.07-10.80)) and for familial primary liver cancer with hepatocellular carcinoma histology (SIR 4.69 (95% CI 1.48-11.04)). For gall bladder and hepatocellular cancer, maternal transmission appeared to be favoured. Gall bladder cancer was associated with pancreatic cancer (SIR 2.39 (95% CI 1.23-4.18)). Primary liver cancer was associated with cervical, urinary bladder, and endocrine gland tumours. Cancer in extrahepatic bile ducts was associated with ovarian cancer and that in ampulla of Vater with thyroid cancer; however, these associations may have been fortuitous. CONCLUSIONS: This study has provided the first data on familial clustering of liver and gall bladder cancers, based on medically confirmed records. The risks were so high that heritable factors were likely to contribute, possibly modified by environmental factors. The demonstration of candidate genes would help to further characterise the familial risks.
Authors: G Hoffmann; G Berglund; S Elmståhl; S Eriksson; H Verbaan; A Widell; S Lindgren Journal: Scand J Gastroenterol Date: 2000-08 Impact factor: 2.423
Authors: M W Yu; H C Chang; Y F Liaw; S M Lin; S D Lee; C J Liu; P J Chen; T J Hsiao; P H Lee; C J Chen Journal: J Natl Cancer Inst Date: 2000-07-19 Impact factor: 13.506
Authors: M Aarnio; R Sankila; E Pukkala; R Salovaara; L A Aaltonen; A de la Chapelle; P Peltomäki; J P Mecklin; H J Järvinen Journal: Int J Cancer Date: 1999-04-12 Impact factor: 7.396
Authors: Robert W Haile; Esther M John; A Joan Levine; Victoria K Cortessis; Jennifer B Unger; Melissa Gonzales; Elad Ziv; Patricia Thompson; Donna Spruijt-Metz; Katherine L Tucker; Jonine L Bernstein; Thomas E Rohan; Gloria Y F Ho; Melissa L Bondy; Maria Elena Martinez; Linda Cook; Mariana C Stern; Marcia Cruz Correa; Jonelle Wright; Seth J Schwartz; Lourdes Baezconde-Garbanati; Victoria Blinder; Patricia Miranda; Richard Hayes; George Friedman-Jiménez; Kristine R Monroe; Christopher A Haiman; Brian E Henderson; Duncan C Thomas; Paolo Boffetta Journal: Cancer Prev Res (Phila) Date: 2012-02
Authors: Jessica L Petrick; Megan Braunlin; Mathieu Laversanne; Patricia C Valery; Freddie Bray; Katherine A McGlynn Journal: Int J Cancer Date: 2016-06-28 Impact factor: 7.396
Authors: Alison L Van Dyke; Margaret S Langhamer; Bin Zhu; Ruth M Pfeiffer; Demetrius Albanes; Gabriella Andreotti; Laura E Beane Freeman; Andrew T Chan; Neal D Freedman; Susan M Gapstur; Graham G Giles; Francine Grodstein; Linda M Liao; Juhua Luo; Roger L Milne; Kristine R Monroe; Marian L Neuhouser; Jenny N Poynter; Mark P Purdue; Kim Robien; Catherine Schairer; Rashmi Sinha; Stephanie Weinstein; Xuehong Zhang; Jessica L Petrick; Katherine A McGlynn; Peter T Campbell; Jill Koshiol Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-01-16 Impact factor: 4.254